Merck Exec: NIH Concerns & China Outlook
- Amid ongoing discussions about the National Institutes of Health (NIH) budget and its potential impact on U.S.
- li acknowledged proposed budget cuts to the NIH but refrained from direct criticism.
- “I’m hopeful that the noise will settle down, and the true value, which is not hard to see, will be seen,” li said.
Merck’s R&D leader, Dean Li, strongly defends NIH funding, highlighting its vital role as a “super-highway for biomedicine”. Li, speaking at the American Society of Clinical Oncology meeting, emphasized the potential risks of proposed budget cuts to the National Institutes of Health. He expressed optimism that policymakers will recognize the NIH’s critical value for US innovation and basic research. News directory 3 reports that Li refrained from direct criticism of proposed cuts, yet warned of a potential shift in research priorities if funding isn’t prioritized. Discover what’s next for NIH funding and the future of biomedical research.
merck Executive Defends NIH Funding Amid Budget Concerns
Amid ongoing discussions about the National Institutes of Health (NIH) budget and its potential impact on U.S. innovation, a top Merck executive emphasized the agency’s critical role. Dean Li,head of research and development at Merck,described the NIH as “an amazing super-highway for biomedicine” at a recent STAT event during the American Society of Clinical Oncology meeting.
li acknowledged proposed budget cuts to the NIH but refrained from direct criticism. He voiced optimism that the agency’s value would be recognized.However, he cautioned that a failure to do so could lead to a shift in basic research priorities.
“I’m hopeful that the noise will settle down, and the true value, which is not hard to see, will be seen,” li said. “But if it isn’t, it can cause a problem, and you will have a shift of basic research.”
What’s next
The future of NIH funding remains uncertain, but industry leaders like Li are advocating for its continued support to foster biomedical innovation and maintain U.S. competitiveness in research and development.